{"id":11760,"date":"2023-01-03T12:06:07","date_gmt":"2023-01-03T17:06:07","guid":{"rendered":"https:\/\/scottburrows.com\/?p=11760"},"modified":"2023-01-03T12:06:07","modified_gmt":"2023-01-03T17:06:07","slug":"scott-burrows-pharmaceutical-sales-speaker-6","status":"publish","type":"post","link":"https:\/\/scottburrows.319heads.com\/scott-burrows-pharmaceutical-sales-speaker-6\/","title":{"rendered":"Scott Burrows, Pharmaceutical Sales Speaker"},"content":{"rendered":"
<\/p>\n
<\/p>\n
As a pharmaceutical industry motivational sales speaker<\/a>, I understand that statistics can be misleading.<\/p>\n According to the latest pharmaceutical industry projections, in 2023 the U.S. industry\u2019s share of the entire industry\u2019s sales worth should be in excess of $685 billion with a nearly 44-percent market share. However, not all of that information reveals the true picture of what to expect. The entire industry is worth $1.5 trillion and clearly, mega-trends are occurring within that huge framework.<\/p>\n In 2023, there will be an expected tightening and controlling of pricing, insurance obstacles, healthcare provider shortages, a decline in the pricing of generic drugs and with it, an expected reduction in research and development expenditures in certain sectors. Obviously, reduced R&D expenditures in certain areas will yield a ripple effect.<\/p>\n